Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
NEW YORK, Aug. 25, 2017 -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
The Phase II clinical trial will investigate the effect of ZLX-1 on insomnia, and is a critical milestone for this novel insomnia treatment on its way to final approval. The trial results are essential for validating the ZLX-1 concept and for designing the Phase IIb trial to follow.
“We are thrilled to finally see the the clinical trial taking off,” says Blake Insomnia Therapeutics president and CEO Birger Jan Olsen. “It is an important milestone for the company and also for me personally, as I’ve been looking forward to this moment for quite some time now.”
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact: Birger Jan Olsen, CEO Blake Insomnia Therapeutics Inc. 1(888) 612-2905 [email protected]
